AMAG Pharmaceuticals (AMAG) Shares are Up 9.91%

AMAG Pharmaceuticals (AMAG) has been under a strong bear grip, hence the stock is down -3.01% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 9.32% in the past 1 week. The stock has risen by 9.91% in the past week indicating that the buyers are active at lower levels, but the stock is down -4.98% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 1.55% and the 50-Day Moving Average is 2.08%.The 200 Day SMA reached 1.04% AMAG Pharmaceuticals, Inc. is up 6.03% in the last 3-month period. Year-to-Date the stock performance stands at -18.42%.


AMAG Pharmaceuticals (AMAG) : 6 Wall Street analysts covering AMAG Pharmaceuticals (AMAG) believe that the average level the stock could reach for the short term is $43.5. The maximum price target given is $80 and the minimum target for short term is around $27, hence the standard deviation is calculated at $18.88.

For the current week, the company shares have a recommendation consensus of Buy. AMAG Pharmaceuticals (NASDAQ:AMAG): stock was range-bound between the intraday low of $24.42 and the intraday high of $25.09 after having opened at $24.82 on Fridays session. The stock finally closed in the red at $24.82, a loss of -1.08%. The stock remained in the red for the whole trading day. The total traded volume was 1,063,070 shares. The stock failed to cross $25.09 in Fridays trading. The stocks closing price on Thursday was $24.63.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.